The most clinically relevant prediction from the current model is that even in inhibiting a single pathway involving VEGF signaling to ERK1/2 and in the absence of any consideration of tumor resistance, combination therapeutic strategies seem to be essential. Here, VEGFA is linked to neoplasm.